ARQT
Arcutis Biotherapeutics, Inc. · Healthcare · Market cap $4.0B
Insiders sold $2.3M net in the last 90 days ·5 sellers, 0 buyers· 5 of 13 sales under Rule 10b5-1 plans· latest Form 4 filed Oct 19, 2026
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$16.3M
reported sales (SEC code S)
Unique Insiders
11
in the rolling window
Latest filing
Oct 19, 2026
Welgus Howard G.
Arcutis Biotherapeutics, Inc. (ARQT) has 66 SEC Form 4 filings (124 transaction rows) in the rolling window, disclosed by 11 distinct insiders. Most recent filing: Oct 19, 2026.
Inside the rolling window, 11 insiders at Arcutis Biotherapeutics, Inc. reported no open-market purchases and 61 open-market sales totaling $16.3M. The most active filer is See Remarks Burnett Patrick with 15 filings. Insiders have net sold $3.2M over the trailing 6 months. The most recent open-market filing is a sale of 4,728 shares by Director Welgus Howard G., dated Oct 15, 2026, worth $127K.
- Industry:Biotechnology
- CEO:Todd Franklin Watanabe
- Employees:354
- HQ:Westlake Village, CA, US
- IPO:2020-01-31
| Source | |||||||
|---|---|---|---|---|---|---|---|
| Director | Sale | 4,728 | $127K | Oct 19 | -0.1% | SEC ↗ | |
| See Remarks | Sale | 3,674 | $92K | Sep 18 | +25.6% | SEC ↗ | |
| Director | Sale | 4,730 | $114K | Sep 17 | +20.4% | SEC ↗ | |
| See Remarks | Sale | 9,989 | $250K | Sep 10 | +36.3% | SEC ↗ | |
| Director | Sale | 38,200 | $956K | Aug 28 | +34.0% | SEC ↗ | |
Curran TerrieFirst filing | Director | Sale | 1,072 | $28K | Aug 24 | +28.6% | SEC ↗ |
| See Remarks | Sale | 1,697 | $46K | Aug 21 | +27.1% | SEC ↗ | |
| Director | Sale | 4,730 | $124K | Aug 19 | +20.4% | SEC ↗ | |
| See Remarks | Sale | 8,300 | $220K | Aug 14 | +21.7% | SEC ↗ | |
| See Remarks | Sale | 6,700 | $175K | Aug 14 | — | SEC ↗ | |
| See Remarks | Sale | 955 | $25K | Aug 6 | — | SEC ↗ | |
Matsuda MasaruFirst in 3 months | See Remarks | Sale | 1,230 | $32K | Aug 6 | — | SEC ↗ |
Watanabe ToddFirst in 3 months | See Remarks | Sale | 4,375 | $114K | Aug 6 | — | SEC ↗ |
| Director | Sale | 4,730 | $127K | Jul 17 | — | SEC ↗ | |
LIN SUE-JEANFirst in 7 months | Director | Sale | 4,946 | $121K | Jun 18 | — | SEC ↗ |
| Director | Sale | 4,096 | $100K | Jun 18 | — | SEC ↗ | |
| Director | Sale | 635 | $16K | Jun 18 | — | SEC ↗ | |
| SVP Chief Financial Officer | Sale | 435 | $9K | May 13 | — | SEC ↗ | |
| See Remarks | Sale | 222 | $5K | May 13 | — | SEC ↗ | |
| See Remarks | Sale | 8,256 | $192K | May 6 | — | SEC ↗ | |
| See Remarks | Sale | 684 | $16K | May 6 | — | SEC ↗ | |
| SVP Chief Financial Officer | Sale | 1,341 | $32K | May 6 | — | SEC ↗ | |
| See Remarks | Sale | 3,172 | $75K | May 6 | — | SEC ↗ | |
| Director | Sale | 7,144 | $164K | May 6 | — | SEC ↗ | |
| Director | Sale | 10,000 | $239K | Apr 3 | — | SEC ↗ |
Earnings: last 7 quarters
Congress trading ARQT 7 all-time
- DRep. Gilbert CisnerosPurchase$1,001 - $15,0002026-05-29
- DRep. Gilbert Ray CisnerosPurchase$1,001 - $15,0002026-05-29
- DRep. Gilbert Ray CisnerosPurchase$1,001 - $15,0002026-03-03
- DRep. Gilbert Ray CisnerosOther$1,001 - $15,0002025-12-11
- DRep. Josh S. GottheimerSale$1,001 - $15,0002023-09-15
- DRep. Josh S. GottheimerPurchase$1,001 - $15,0002023-04-17
STOCK Act disclosures are filed up to 45 days after the trade. Amount is a disclosed range, not an exact figure.
Frequently asked questions
How many SEC Form 4 insider filings does ARQT have?
Arcutis Biotherapeutics, Inc. (ARQT) has 66 SEC Form 4 filings (124 transaction rows) in the rolling 365-day window, disclosed by 11 distinct insiders. Most recent filing: Oct 19, 2026.
When was the most recent SEC Form 4 filing for ARQT?
The most recent Form 4 filing for ARQT on Tracefour is dated Oct 19, 2026.
Who is the most active insider at ARQT?
The most active SEC Form 4 filer at ARQT in the rolling window is See Remarks Burnett Patrick, with 15 filings.
What is the net insider flow at ARQT over the last 6 months?
Over the trailing 180 days, insiders at ARQT have net sold $3.2M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at ARQT in the current window?
Inside the rolling window, insiders at ARQT bought $0 and sold $16.3M based on SEC Form 4 filings.
Can I get alerts for ARQT insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Arcutis Biotherapeutics, Inc. (ARQT). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Arcutis Biotherapeutics, Inc. is in the Healthcare sector.